Skip to search boxSkip to navigationSkip to main content

Association of the COVID-19 Pandemic With Rates of Prostate Cancer Biopsies and Diagnoses in Black vs White US Veterans

  • Zachary Klaassen(corresponding author)
    ,
  • Shannon Stock
    ,
  • Justin Waller
    ,
  • Amanda De Hoedt
    ,
  • Stephen J. Freedland
*Corresponding author for this work
  • ,
  • ,
  • College of the Holy Cross
    ,
  • Durham Veterans Affairs Health Care System
    ,
  • Cedars-Sinai Medical Center
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

IMPORTANCE Several studies have assessed the negative effect of the COVID-19 pandemic on cancer screening and diagnosis rates. However, this has not been evaluated for prostate biopsy and prostate cancer (PC) diagnosis in an equal-access health care system. OBJECTIVE To determine the association of the pandemic with prostate biopsy and PC diagnosis rates among Black vs White patients in the Veterans Affairs Health Care System (VAHCS). DESIGN, SETTING, AND PARTICIPANTS This cohort study included a retrospective analysis of all prostate biopsies performed on patients in the VAHCS without a preexisting PC diagnosis between January 2018 and March 2021. The base population included all living male patients who had at least 1 visit to the VAHCS during the 3 years prior to each month of the study. EXPOSURE The COVID-19 pandemic. MAIN OUTCOMES AND MEASURES The main outcomes were the number of prostate biopsies and PC diagnoses by month. The influence of the pandemic on prostate biopsy volume and the incidence of PC diagnoses was modeled using an interrupted time-series analysis. Poisson generalized linear models were fitted to project the expected number of prostate biopsies and PC diagnoses had there been no pandemic interruption. Additional models were used to test for differences by race. RESULTS Prior to the pandemic (January 2018 through February 2020), monthly biopsy numbers among 51 606 included men ranged between 1230 and 1695, of which 56% to 60% of results were positive for PC. The estimated number of missed PC diagnoses from March 2020 through March 2021 ranged from 97 cases (October 2020: 752 cases expected, 655 cases observed) to 573 cases (April 2020: 794 cases expected, 221 cases observed). Prior to the pandemic, biopsy rates were statistically significantly higher among Black vs White men (incidence rate ratio, 2.25; 95% CI, 2.06-2.46; P < .001). There was no change in biopsy rates associated with race at the onset of the pandemic nor during the recovery period from March 2020 to March 2021. Similar trends were observed for PC diagnosis rates. CONCLUSIONS AND RELEVANCE Results of this cohort study demonstrate that during the COVID-19 pandemic, prostate biopsy and PC diagnosis rates decreased, particularly during the peak of the pandemic. However, there were no statistically significant changes in rates by race.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 914-918 (5 pages)

Journal (Volume, Issue Number)

JAMA Oncology (Volume 8, Issue 6)

Publication milestones

  • Accepted/In press - 2022
  • Published - 06/2022

Publication status

Published - 06/2022

ISSN

2374-2437

Publication IDs

  • Scopus: 85128894276
  • PubMed: 35389461

Publication metrics

Metrics

Fractional count
1
Fractional count
0.20
Fractional count
4
Fractional count
0.80
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
11
Mentions
7
Captures
19

Funding Details

reported grant funding from the US Department of Defense, as well as advisory board involvement with Bayer, Astellas/Pfizer, Myovant/Pfizer, and Blue Earth Diagnostics outside the submitted work. Ms De Hoedt reported grants from Janssen, Genomic Health, Ferring, Merck, LungLife AI, Blue Earth Diagnostics, Myriad, DiaSorin, MDxHealth, and Pfizer outside the submitted work. No other disclosures were reported.
FundersFunding numbers
DOD
-
Pfizer
-
Janssen Pharmaceuticals
-